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Abstract
Background: Clinical management of cardiac resynchronization therapy (CRT) non-responders is 
difficult, and their prognosis is poor. The aim of the present study was to evaluate whether treatment with 
sacubitril/valsartan can improve quality of life (QoL) parameters in these patients. 
Methods: Thirty five non-responders to CRT were included (75 ± 7 years, 28% females, mean left 
ventricular ejection fraction 28 ± 8%, 54% non-ischemic cardiomyopathy) with maximally optimized 
drug therapy and New York Heart Association class II–III. They were all on angiotensin-converting 
enzyme inhibitors or angiotensin II receptor blockers and were switched to sacubitril/valsartan. One 
week before and 6 months after initiation of the therapy they completed both the Minnesota Living with 
Heart Failure (MLWHF) and the 12-item Kansas City Cardiomyopathy Questionnaires (KCCQ-12). 
The primary outcome was the effect of sacubitril/valsartan on the physical, clinical, social and emotional 
QoL parameters and number of hospitalizations. 
Results: The mean total scores of both questionnaires improved from baseline to the follow-up visit 
at 6-months (KCCQ-12 40 ± 10 to 47 ± 10; p < 0.001; MLWHF 40 ± 15 to 29 ± 15; p < 0.001). 
The best results were seen in the KCCQ-12 total symptom domains (77% improvement), the MLWHF 
physical domain (81% improvement), and the MLWHF emotional domain (71% improvement). Two 
patients died during follow-up. The mean number of hospitalizations reduced significantly (1 ± 0.6 vs. 
0.5 ± 0.8; p = 0.003)
Conclusions: In CRT non-responders, sacubitril/valsartan significantly improved overall QoL, physi-
cal limitations and emotional domains and reduced the number of hospitalizations. (Cardiol J 2021; 
28, 3: 402–410)
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Cardiac resynchronization therapy (CRT) is 
the therapeutic option of choice for patients with 
heart failure (HF) and conduction disorders [1, 2], 
but 30% to 40% of them are considered non-
-responders and have a poor quality of life (QoL). 
The reasons are diverse: type of cardiomyopathy, 
previous non-left bundle branch block morphology, 
comorbidity factors, suboptimal left ventricular 
(LV) lead position or inadequate pacing optimiza-
tion [3, 4]. Management of these patients is diffi-
cult, and they are a particularly high-risk HF group 
with < 50% survival at 5 years [5]. The presence of 
significantly limited QoL is becoming increasingly 
relevant for health care stakeholders, as HF is one 
of the main causes of poor QoL. 
Sacubitril/valsartan is a new angiotensin re-
ceptor neprilysin inhibitor (ARNI), and are a class I 
recommendation for patients with chronic HF, re-
duced LV ejection fraction (LVEF) and New York 
Heart Association (NYHA) class II–IV instead of 
angiotensin-converting enzyme inhibitors (ACEIs) 
or angiotensin II receptor blockers (ARBs) in con-
junction with other standard HF treatments [2]. 
Data on the clinical benefit of sacubitril/valsartan 
in patients with CRT are scarce, because very few 
patients with these devices have been included 
in trials (usually less than 20%) [6, 7], although 
some sub-group analyses have demonstrated that 
they experience similar clinical beneficial effects 
to those of patients without CRT. The aim of the 
current study was to determine whether admin-
istering sacubitril/valsartan instead or an ACEI/ 
/ARB in non-responders to CRT could result in 
a beneficial effect on morbidity and QoL. 
Methods
Patients with CRT were included (CRT-D defi-
brillator or CRT-P pacing only) who were referred 
to the cardiology HF/arrhythmia outpatient clinics 
from the Fundación Jiménez Díaz (FJD; Madrid, 
Spain) and the Hospital Central de la Defensa 
(HCD; Madrid, Spain). They needed to fulfill the 
following criteria before enrollment: 1) age > 18 
years; 2) recipient of a CRT device for > 6 and < 36 
months for standard indications; 3) optimized medi-
cal therapy since implantation, including ACEI/ 
/ARB; 4) naïve to sacubitril-valsartan; 5) presence 
of sinus rhythm, or atrial fibrillation (AF) with spon-
taneous or induced complete atrioventricular block; 
6) at least > 95% LV stimulation; 7) unchanged or 
worsened clinical status by CRT, according to the 
HF composite end point described by Packer [8], 
in the absence of a reversible cause. Exclusion 
criteria were: 1) systolic blood pressure (SBP) 
< 100 mmHg; 2) estimated glomerular filtration 
rate (eGFR) < 30 mL/m/1.73 m2 or chronic renal 
dialysis; 3) serum potassium levels > 5.2 mmol/L; 
4) severe anemia (hemoglobin < 9 mg/dL) or thy-
roid disease; 5) life-expectancy < 1 year because 
of concomitant, non-cardiovascular disorders; 
6) history of stroke, myocardial infarction, or un-
stable angina pectoris within the prior 3 months; 
7) presence of correctible valvular disease; 8) subject 
unable to attend follow-up at the study site or unable, 
for physical or mental reasons, to comply with the 
trial procedures, or to sign the informed consent; 
9) subject participates in another research project.
As in the PARADIGM-HF trial, all patients 
taking ACEI/ARB were considered for participa-
tion, but they were required to take a stable dose 
of a beta-blocker (BB) and an ACEI/ARB dose 
equivalent to at least 10 mg of enalapril daily for 
a minimum of 4 weeks prior to screening [6]. 
After inclusion, ACEI/ARB was suspended and 
sacubitril/valsartan was initiated after 36 hours, 
at an initial dose of 24/26 mg. All the patients 
continued with the same BB, mineralocorticoid 
receptor antagonist (MRA) or diuretic dose un-
less they experienced symptoms due to sustained 
SBP < 90 mmHg. After 1 month, the sacubitril/ 
/valsartan dose was titrated according to the initial 
response of the patient, tolerability of the drug and 
patient characteristics, always trying to achieve 
the highest doses. 
One week prior to inclusion in the study, all 
patients filled in two QoL questionnaires: Min-
nesota Living with Heart failure (MLWHF) [9] 
and 12-item Kansas City Cardiomyopathy Ques-
tionnaire (KCCQ-12) [10], to establish their clini-
cal status before enrollment. The MLWHF is 
a self-administered disease-specific questionnaire 
comprising 21 items answered on a 6-point Likert 
scale, representing different degrees of impact of 
HF on QoL, from 0 (none) to 5 (very much) [11]. 
It provides a total score (range 0–105, from best 
to worse), as well as scores for two dimensions, 
physical (range 0–40) and emotional (range 0–25). 
The other 8 items are only considered for the cal-
culation of the total score. The KCCQ-12 quantifies 
8 domains of patients’ HF-related health status: 
Physical Limitation (3 items); Swelling frequency 
(1 item); Fatigue frequency (1 item); Dyspnea 
frequency (1 item); Dyspnea — sleeping upright 
(1 item); Enjoyment of life (1 item); Rest of life as 
is now (1 item); Social limitation (3 items). Item 
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responses are coded sequentially (1, 2, 3, etc.) from 
worst to best status. For analysis, five domains are 
calculated: Physical limitation, Symptoms, Life 
status, Social limitation, and an Overall summary 
score. Both questionnaires have been translated 
into Spanish and have been validated [12, 13].
Clinical and demographic data were obtained 
for every patient: sex; age; presence of cardiovas-
cular risk factors (diabetes mellitus, hypertension, 
and smoking) and chronic obstructive pulmonary 
disease; time from CRT implantation to study 
inclusion; type of cardiomyopathy (ischemic, non-
ischemic); type of CRT device; and drugs used. 
The following data were also collected before inclu-
sion and after 6 months: eGFR; potassium levels; 
hemoglobin levels; and NYHA class. A baseline 
echocardiographic study was performed in all pa-
tients, including end-diastolic LV diameter (mm), 
end-diastolic right ventricular diameter (mm), 
LVEF, and left atrium (LA) size (mm) measure-
ments. Patients were divided according the type 
of CRT device. 
The primary outcome was any change from 
baseline to the 6-month follow-up visit in all the 
items and total domains analyzed from both the 
KCCQ-12 and the MLWHF questionnaires. The 
secondary end point was to compare the number 
of hospitalizations (> 24-h before discharge)/ 
/Emergency Department consultations (< 24-h 
before discharge) because of HF 6 months before 
the inclusion and at 6-month follow-up. All patients 
provided written informed consent. The study pro-
tocol was approved by the hospital’s Institutional 
Review Board. The study complied with the tenets 
of the Declaration of Helsinki.
Statistical analysis
Continuous values were expressed as mean 
± standard deviation and nominal variables as 
counts and percentages. Median values with the 
corresponding interquartile range (IQR) were 
computed for non-normally distributed variables. 
A two-tailed t-test was used for comparison of 
normally-distributed variables, and the non-para-
metric Kruskal-Wallis test for values that were 
not normally distributed. For comparisons of 
categorical data, two-tailed c2 statistics with the 
Yates correction or the Fisherexact test were 
used, as applicable. Mean values were calculated 
from patient scores of both questionnaires for all 
domains. Values were obtained at baseline and 
after a 6-month follow-up period. The principal ef-
ficacy analysis was the change in mean total scores 
and individual domains between baseline and the 
follow-up visit at 6 months. In the MLWHF total 
score, patients were divided into cohorts on the 
basis of change as follows: worse (∆ ≥ +6 points), 
similar, (∆ < +6 and < –6 points), better (∆ ≥ –6 
points). Similar cohorts were made for the spe-
cific domains (Physical, Emotional, Rest) but with 
a difference of 2 points in each of them. Similarly, 
in the 12-KCCQ overall summary score, patients 
were divided into cohorts on the basis of change 
as follows: worse (∆ ≥ –4 points), similar (∆ < –4 
and < 4 points), better (∆ ≥ +4 points). Similar 
cohorts were made for the four specific domains 
but with a difference of 1 point in each of them. 
Missing values were not accounted for in the pri-
mary analysis. A value of p < 0.05 was considered 
to indicate a statistically significant difference. All 
analyses were done using IBM® SPSS® Statistics 
version 20.0.0 (Armonk, NY, USA).
Results
Tables 1 and 2 show the clinical characteris-
tics of the patients by CRT type. 35 patients were 
included (mean age 75 ± 7 years, 28% females). 
Patients with CRT-P were significantly older com-
pared with those with CRT-D (78 ± 6 vs. 73 ± 8 
years; p = 0.029), and with a higher mean LVEF 
(32 ± 5 vs. 25 ± 9, respectively; p = 0.005). Mean 
time from CRT device implantation to inclusion in 
the study was 23 ± 17 months. 
After initiation of sacubitril/valsartan, 6 (20%) 
patients experienced persistent SBP < 90 mmHg, 
but only one of them did not definitively tolerate 
the drug. In the remaining 5 patients the BB and/or 
diuretic dose was adjusted, and the drug was main-
tained at the 24/26 mg dose. Although the highest 
doses of sacubitril/valsartan were intended, after 
6 months 46% of patients remained on the same 
dose and 50% used the 49/51 mg dose. There was 
only a slight but significant deterioration in eGFR 
(58 ± 16 to 54 ± 17 mL/min/1.73 m2; p < 0.001) 
after administration of the drug. Two patients died 
because of refractory HF before completing the 
6-month follow-up. Two patients needed outpatient 
treatment with levosimendan, also maintaining the 
lower dose of sacubitril/valsartan. 
The mean number of hospitalizations/Emergen-
cy Department consultations reduced significantly 
after the 6-month follow-up (1 ± 0.6 to 0.5 ± 0.8 
(p < 0.001). Although there was a slight increase 
in LVEF after the 6-month follow-up, it was not 
statistically significant (27 ± 8 vs. 28 ± 8; p = 0.09).
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Changes in QoL questionnaires
The KCCQ-12 baseline total physical limita-
tion domain was worse in the CRT-P group, without 
any significant differences in the baseline of the 
remaining scores (Table 3). After the 6-month 
follow-up visit, 31 patients filled in both question-
naires (2 patients died because of refractory HF 
and 2 patients were lost to follow-up). 
Table 4 show the status after the 6-month 
follow-up visit for the different scores analyzed. 
The best results were obtained in the KCCQ-12 
total physical limitation and total symptom domains 
Table 1. Clinical characteristics of patients included.
All CRT-P CRT-D P 
Number 35 15 20
Age 75 ± 7 78 ± 6 73 ± 8 0.029
Female sex 10 (28%) 9 (60%) 1 (5%) < 0.001
Diabetes 14 (40%) 7 (47%) 7 (35%) 0.363
Hypertension 30 (86%) 11 (73%) 19 (95%) 0.093
Dyslipidemia 24 (69%) 7 (47%) 17 (85%) 0.020
Former smoker 9 (23%) 1 (7%) 8 (35%) 0.055
BMI [kg/m2] 26 ± 4 25 ± 4 27 ± 3 0.154
Ischemic disease 16 (46%) 1 (7%) 15 (75%) < 0.001
Non-ischemic 19 (54%) 14 (93%) 5 (25%) < 0.001
Beta-blockers 34 (97%) 14 (93%) 20 (100%) 0.429
Diuretics 35 (100%) 15 (100%) 20 (100%) –
MRA 12 (34%) 1 (7%) 11 (55%) 0.003
Amiodarone 11 (31%) 3 (20%) 8 (40%) 0.187
Digoxin 2 (6%) 1 (7%) 1 (5%) 0.681
SGTL2 10 (28%) 5 (33%) 5 (25%) 0.433
Atrial fibrillation 12 (34%) 6 (40%) 6 (30%) 0.397
NYHA class II 29 (83%) 14 (93%) 15 (75%) 0.167
NYHA class III 6 (17%) 1 (7%) 5 (25%) 0.167
eGFR 57 ± 16 53 ± 15 60 ± 17 0.224
Potassium [mmol/mL] 4.4 ± 0.3 4.4 ± 0.3 4.5 ± 0.3 0.564
Hemoglobin [mg/dL] 13 ± 1.4 13 ± 1.3 13 ± 1.4 0.843
SBP [mm Hg] 120 ± 12 120 ± 14 120 ± 11 0.939
CRT-P — cardiac resynchronization therapy pacing only; CRT-D — cardiac resynchronization therapy with defibrillator; BMI — body mass index; 
eGFR — estimated glomerular filtration rate; MRA — mineralocorticoid receptor antagonist; SGTL2 — inhibitors of sodium-glucose contansporter-2; 
NYHA — New York Heart Association; SBP — systolic blood pressure
Table 2. Echocardiographic parameters and QRS width of patients included.
All CRT-P CRT-D P 
Number 35 15 20
LA [mm] 45 ± 9 45 ± 6 46 ± 10 0.628
LVEDD [mm] 57 ± 7 55 ± 5 58 ± 7 0.116
RVEDD [mm] 41 ± 5 40 ± 6 41 ± 4 0.383
LVEF [mm] 28 ± 8 32 ± 5 25 ± 9 0.005
QRS width pre-CRT [ms] 150 ± 30 144 ± 30 155 ± 30 0.310
QRS width with CRT [ms] 136 ± 12 132 ± 13 140 ± 11 0.090
CRT-P — cardiac resynchronization therapy pacing only; CRT-D — cardiac resynchronization therapy with defibrillator; LA — left atrium; 
LVEDD — left ventricular end-diastolic diameter; RVEDD — right ventricular end-diastolic diameter; LVEF — left ventricular ejection fraction
www.cardiologyjournal.org 405
José Manuel Rubio Campal et al., Resynchronization plus neprilysin/angiotensin inhibitor
(72% were better in both) and also in the MLWHF 
physical and emotional domains (81% and 71% 
were better, respectively). In the KCCQ-12 overall 
summary score, 65% of patients were better, 19% 
similar and 16% worse. When the emotional and 
social domains were analyzed, in the KCCQ-12 
life status domain, 48% of the patients were bet-
ter, 42% similar and 10% worse. In the KCCQ-12 
social limitation domain, 39% were better, 39% 
similar and 22% worse. In the MLWHF emotional 
domain, 71% were better, 26% similar and only 3% 
worse. No significant differences between CRT-D 
and CRT-P patients in all the domains analyzed 
were demonstrated. Table 5, Figures 1 and 2 show 
the mean value of all the scores at baseline and at 
6-month follow-up, demonstrating a significant im-
provement in all domains except for the KCCQ-12 
Social limitations. 
Discussion
Quality of life has been defined by the World 
Health Organization (WHO) as a broad-ranging con-
cept affecting physical health, psychological state 
and social relationships [14]. Moreover, achieving 
a better QoL in patients with HF is important regard-
less of the device or drug used, because a decrease 
in mortality or morbidity is not always accompanied 
by better QoL. BBs do not significantly improve 
QoL [15], and ACEI/ARBs have demonstrated mixed 
results [16], although many trials were conducted 
without using actual HF-specific QoL questionnaires 
like the ones used in the present study. On the other 
hand, sacubitril/valsartan is one of the few HF thera-
pies that have demonstrated a significant improve-
ment in morbidity and mortality as well as in physical 
and social activity limitations [17, 18]. 
Table 3. Baseline quality of life domains of patients included
Baseline QoL domains CRT-P CRT-D P 
KCCQ-12 Total physical limitation 8 ± 2 10 ± 3 0.04
KCCQ-12 Total symptoms 16 ± 4 17 ± 4 0.531
KCCQ-12 Life status 5 ± 2 6 ± 2 0.089
KCCQ-12 Social limitations 9 ± 3 10 ± 4 0.310
KCCQ-12 Overall summary 37 ± 9 42 ± 11 0.185
MLWHF Physical 21 ± 6 18 ± 7 0.222
MLWHF Emotional 12 ± 5 10 ± 5 0.248
MLWHF Total 41 ± 14 40 ± 17 0.825
CRT-P — cardiac resynchronization therapy pacing only; CRT-D — cardiac resynchronization therapy with defibrillator; QoL — quality of life; 
KCCQ-12 — Kansas City Cardiomyopathy Questionnaire; MLWHF — Minnesota Living with Heart Failure
Table 4. Clinical situation after 6-month treatment with sacubitril/valsartan.
Domains at follow-up Result
CRT-P (n = 14) CRT-D (n = 17)
Better Similar Worse Better Similar Worse
KCCQ-12 Total physical limitation 10 (72%) 3 (21%) 1 (7%) 12 (71%) 5 (29%) 0 (0%)
KCCQ-12 Total symptoms 10 (72%) 4 (28%) 0 (0%) 14 (82%) 2 (12%) 1 (6%)
KCCQ-12 Life status 7 (50%) 6 (43%) 1 (7%) 8 (47%) 7 (41%) 2 (12%)
KCCQ-12 Social limitations 6 (44%) 5 (35%) 3 (21%) 6 (35%) 7 (41%) 4 (24%)
KCCQ-12 Overall summary 10 (72%) 1 (7%) 3 (21%) 10 (59%) 5 (29%) 2 (12%)
MLWHF Physical 12 (86%) 1 (7%) 1 (7%) 13 (77%) 3 (17%) 1 (6%)
MLWHF Emotional 10 (72%) 3 (21%) 1 (7%) 12 (71%) 5 (29%)5 0 (0%)
MLWHF Total 12 (86%) 2 (14%) 0 (0%) 14 (83%) 3 (17%) 0 (0%)
CRT-P — cardiac resynchronization therapy pacing only; CRT-D — cardiac resynchronization therapy with defibrillator; KCCQ-12 — Kansas City 
Cardiomyopathy Questionnaire; MLWHF — Minnesota Living with Heart Failure; Better, Similar, Worse, Improvement, similar status, worse in 
each of the specific quality of life domains
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This is the first study to provide evidence that 
adding sacubitril/valsartan to CRT non-responders 
is associated with an improvement in most HF-
-specific QoL domains. More specifically, there was 
a significant improvement in physical activities and 
symptoms, which were the maximum limitations of 
patients at baseline. Also, the improvement in the 
social and emotional domains was very relevant. 
This is important for all patients, but particularly 
for those with chronic HF, as most of them feel that 
they have a chronic disease with a poor prognosis 
and generally have a poor QoL. The general answer 
when adding sacubitril/valsartan is that patients 
say they “feel better now”, and this resulted in 
a better status in emotional QoL domains.
For the analysis, we decided to differentiate 
between CRT-D and CRT-P devices because CRT-P 
patients were older, more frequently female and with 
non-ischemic cardiomyopathy, but the results in QoL 
improvement were similar in both groups, demon-
strating a good effect of the drug regardless of the 
CRT type and patient characteristics [19].
One important fact in the present study is 
that the mean age was 75 ± 7 years, much higher 
than in other large, randomized trials with sacu-
bitril/valsartan (64 ± 11 and 63 ± 11 years in the 
PARADIGM-HF [6] and PRIME [20] trials, respec-
tively). This is important because before this study, 
it was assumed that some baseline physical limita-
tions of the patients could be related more to age 
or muscular or neurological disorders rather than 
to HF symptoms, but surprisingly, most of them 
experienced a better physical situation, something 
that could be related to the better perception in 
Table 5. Mean ± standard deviation values of different quality of life domains pre and after 6-month 
treatment with sacubitril/valsartan (S/V).
Quality of life domains Pre S/V Post S/V P 
KCCQ-12 Total physical limitation 9 ± 2 11 ± 3 < 0.001
KCCQ-12 Total symptoms 16 ± 4 19 ± 5 0.001
KCCQ-12 Life status 6 ± 2 7 ± 2 0.009
KCCQ-12 Social limitations 9 ± 3 10 ± 3 0.228
KCCQ-12 Overall summary 40 ± 10 47 ± 10 0.001
MLWHF Physical 19 ± 7 13 ± 6 < 0.001
MLWHF Emotional 11 ± 5 8 ± 6 < 0.001
MLWHF Total 40 ± 15 29 ± 15 < 0.001
KCCQ-12 — Kansas City Cardiomyopathy Questionnaire; MLWHF — Minnesota Living with Heart Failure
Figure 1. Kansas City Cardiomyopathy Questionnaire 
(KCCQ-12) overall summary scores at baseline and after 
6-months of treatment with sacubitril/valsartan.
Figure 2. Minnesota Living with Heart Failure (MLWHF) 
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their QoL emotional domains. Depression and 
anxiety are not systematically studied in patients 
with HF, but they are very important components of 
QoL [21, 22]. Dereli et al. [23] have demonstrated 
a significant positive effect of sacubitril/valsartan 
on different depression and anxiety parameters 
in patients with HF and a reduced LVEF. In this 
study, 43% of the patients had clinically significant 
depressive symptoms at baseline, and 38% of them 
also had moderate to severe anxiety, and these was 
related to poor QoL scores regardless of functional 
status. Carels [24] have also reported a stronger 
relationship between QoL and functional capacity 
rather than cardiac function in HF patients and 
an improvement in functional capacity leading to 
better QoL. 
Results herein are similar to other studies with 
sacubitril/valsartan. Chandra et al. [17] reported 
a significant improvement in nearly all KCCQ-12 
physical and social activities compared with enal-
april, with the largest responses in household 
chores and sexual relations, but also with a sig-
nificantly 5-point or greater improvement in the 
combined physical and social activity mean scores. 
Also, at baseline, patients with the greatest limi-
tations attributable to HF in physical and social 
activities were older, more likely to be women, 
and more likely to have a worse NYHA class. In 
addition, the authors reported a reduced likelihood 
of cardiovascular death, all-cause mortality, and 
HF hospitalizations. One important limitation as 
pointed out by the authors of this study is that the 
patients did not complete their baseline KCCQ-12 
until randomization, and so we decided to conduct 
the baseline study 1 week prior to inclusion, to know 
the real situation of the patients before using the 
drug. In a study by Lewis et al. [18], the authors also 
reported a significant improvement in the different 
KCCQ-12 scores and KCCQ-12 overall summary 
scores in patients treated with sacubitril/valsartan 
compared with those treated with enalapril, with 
consistency in most domains, and this persisted 
during the follow-up that lasted over 8 months.
It was decided to set the follow-up visit at 
6 months, to be sure that the initial effect of the 
drug was maintained in the long-term, although in 
most of the studies with sacubitril/valsartan the 
different positive effects can be seen in the first 
2 months. In the PIONEER-HF [7], the authors 
reported an early separation of the event curves for 
clinically relevant end points. Examining the end 
points of cardiovascular death or hospitalization 
for HF, they observed an early effect of sacubitril/ 
/valsartan with the initiation of in-hospital treatment 
for 8 weeks, something consistent with the efficacy 
of the drug in chronic HF patients in other studies.
Limitations of the study
The present study has some limitations. First-
ly, although the results are the first to point out the 
benefit of sacubitril/valsartan in CRT non-respond-
er patients, the population was relatively small, 
so the findings should be further corroborated in 
a larger study. Another important limitation of the 
current study is that although the highest doses 
of sacubitril/valsartan were intended, 46% of the 
patients remained on the same initial dose, 51% had 
the 49/52 mg dose, and no patients received the 
highest dose. Mean baseline SBP of the patients 
was 120 ± 12 mmHg, similar to other studies, but 
as pointed out before, our patients were signifi-
cantly older and had a longer HF history, perhaps 
reflecting a real-life situation. Taking in account 
these characteristics, we decided to be cautious 
when achieving the highest doses to avoid renal 
failure or significant hypotension. The incidence 
of hypotension was 20%, similar to other stud-
ies, and only 1 patient decided to discontinue the 
drug definitively. Several studies with sacubitril/ 
/valsartan have demonstrated that achieving the 
highest dose is difficult, and usually only half of 
the patients are on the highest drug dose [25]. In 
the PARADIGM-HF trial [6], 42% had a reduced 
dose, and in the PIONEER trial [26] only 55% of 
the patients had the highest dose. In a real-life 
study by Du et al. [27], at the 6-month follow-up 
visit 27% of patients had the highest dose, 41% 
the mean dose and 32% the lowest dose. In elderly 
patients, dose reduction or discontinuation of the 
drug has been associated with hypotension and/or 
onset of renal failure. In spite of this, Vardeny et 
al. [28] have demonstrated that although drug re-
duction identified patients at higher risk of a major 
cardiovascular event, the benefit for patients on 
lower doses of sacubitril/valsartan compared with 
those on lower doses of enalapril was similar to that 
of patients who remained on target doses for both 
drugs. All these data suggest that patients taking 
doses lower than the target doses of the drug would 
still derive greater benefit from sacubitril/valsartan 
when compared with enalapril [29]. 
Conclusions
In non-responder patients to CRT despite 
optimal medical treatment, sacubitril/valsartan sig-
nificantly improved overall QoL, physical limitation 
and emotional scores and reduced the number of 
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hospitalizations. New controlled studies are needed 
to validate these results and to extend this benefit 
to more patients.
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